{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:56:10Z","timestamp":1790934970086,"version":"4.1.0"},"reference-count":121,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T00:00:00Z","timestamp":1292976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] is an acyclic nucleoside analog approved since 1996 for clinical use in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Cidofovir (CDV) has broad-spectrum activity against DNA viruses, including herpes-, adeno-, polyoma-, papilloma- and poxviruses. Among poxviruses, cidofovir has shown in vitro activity against orthopox [vaccinia, variola (smallpox), cowpox, monkeypox, camelpox, ectromelia], molluscipox [molluscum contagiosum] and parapox [orf] viruses. The anti-poxvirus activity of cidofovir in vivo has been shown in different models of infection when the compound was administered either intraperitoneal, intranasal (aerosolized) or topically. In humans, cidofovir has been successfully used for the treatment of recalcitrant molluscum contagiosum virus and orf virus in immunocompromised patients. CDV remains a reference compound against poxviruses and holds potential for the therapy and short-term prophylaxis of not only orthopox- but also parapox- and molluscipoxvirus infections.<\/jats:p>","DOI":"10.3390\/v2122803","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T12:31:55Z","timestamp":1293021115000},"page":"2803-2830","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":169,"title":["Cidofovir Activity against Poxvirus Infections"],"prefix":"10.3390","volume":"2","author":[{"given":"Graciela","family":"Andrei","sequence":"first","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KULeuven, Minderboredersstraat 10, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KULeuven, Minderboredersstraat 10, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2010,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"Holy","year":"1986","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"Sakuma","year":"1987","journal-title":"Antivir. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1021\/jm030932o","article-title":"5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acycli c nucleoside phosphonate analogues with antiviral activity","volume":"46","author":"Hockova","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1081\/NCN-200059772","article-title":"Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines","volume":"24","author":"Andrei","year":"2005","journal-title":"Nucleos. Nucleot. Nucleic Acids"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1016\/j.bmc.2004.04.002","article-title":"Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds","volume":"12","author":"Hockova","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1021\/jm0707166","article-title":"Ester Prodrugs of Cyclic 1-(S)- [3-Hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: Synthesis and Antiviral Activity","volume":"50","author":"Krecmerova","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/jm061281+","article-title":"Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds","volume":"50","author":"Krecmerova","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(02)00198-5","article-title":"In vitro activity of potential anti-poxvirus agents","volume":"57","author":"Kern","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(02)00008-6","article-title":"Cidofovir in the treatment of poxvirus infections","volume":"55","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0166-3542(02)00196-1","article-title":"Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections","volume":"57","author":"Baker","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1128\/AAC.47.7.2193-2198.2003","article-title":"Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication","volume":"47","author":"Keith","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0166-3542(00)00130-3","article-title":"Parapoxviruses are strongly inhibited in vitro by cidofovir","volume":"48","author":"Nettleton","year":"2000","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1128\/AAC.01626-08","article-title":"Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir","volume":"53","author":"Vigne","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1128\/AAC.49.12.4843-4852.2005","article-title":"Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","first-page":"1561","article-title":"Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients","volume":"3","author":"Snoeck","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1177\/135965350701200802","article-title":"Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures","volume":"12","author":"Duraffour","year":"2007","journal-title":"Antivir. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0166-3542(91)90063-W","article-title":"Cellular uptake of phosphonylmethoxyalkylpurine derivatives","volume":"16","author":"Palu","year":"1991","journal-title":"Antivir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0006-2952(93)90670-R","article-title":"Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells","volume":"46","author":"Connelly","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0026-895X(25)09608-7","article-title":"Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells","volume":"50","author":"Cihlar","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1749-6632.1990.tb17859.x","article-title":"Biochemical pharmacology of acyclic nucleotide analogues","volume":"616","author":"Bronson","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0026-895X(25)08828-5","article-title":"Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine","volume":"41","author":"Ho","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0026-895X(25)08630-4","article-title":"Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates","volume":"47","author":"Aduma","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/0006-2952(96)00100-1","article-title":"Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase","volume":"51","author":"Xiong","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/0006-2952(94)90600-9","article-title":"Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma","volume":"48","author":"Cherrington","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: A key class of antiviral drugs","volume":"4","author":"Holy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.41.3.594","article-title":"Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation","volume":"41","author":"Xiong","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/AAC.01172-07","article-title":"Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand","volume":"52","author":"Magee","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005","article-title":"Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate","volume":"49","author":"Magee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11477","DOI":"10.1128\/JVI.01061-09","article-title":"Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus","volume":"83","author":"Jesus","year":"2009","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/sj.jid.5701161","article-title":"Cidofovir diphosphate inhibits molluscum contagiosum virus DNA polymerase activity","volume":"128","author":"Watanabe","year":"2008","journal-title":"J. Invest Dermatol."},{"key":"ref_32","unstructured":"Andrei, G., and Snoeck, R. (2010). Kucer\u2019s the Use of Antibiotics, Hodder Arnold."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1128\/JVI.00605-06","article-title":"Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice","volume":"80","author":"Andrei","year":"2006","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1743-422X-5-58","article-title":"Isolation and characterization of cidofovir resistant vaccinia viruses","volume":"5","author":"Becker","year":"2008","journal-title":"Virol. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1128\/AAC.00380-06","article-title":"Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype","volume":"50","author":"Kornbluth","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1128\/JVI.02255-08","article-title":"The 3'-to-5' exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination","volume":"83","author":"Gammon","year":"2009","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1743-422X-7-110","article-title":"Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus","volume":"7","author":"Farlow","year":"2010","journal-title":"Virol. J."},{"key":"ref_38","unstructured":"Andrei, G., Fiten, P., Duraffour, S., Opdenakker, G., and Snoeck, R. (, January May). Characterization of cowpox virus (CPV) mutants arising under pressure with different acyclic nucleoside phosphonates. Presented at the 22nd International Conference on Antiviral Research (22nd ICAR), Miami, FL, USA."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"12520","DOI":"10.1128\/JVI.01528-08","article-title":"Mechanism of antiviral drug resistance of vaccinia virus: Identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs","volume":"82","author":"Gammon","year":"2008","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0166-3542(02)00199-7","article-title":"A review of compounds exhibiting anti-orthopoxvirus activity in animal models","volume":"57","author":"Smee","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/095632020801900302","article-title":"Progress in the discovery of compounds inhibiting orthopoxviruses in animal models","volume":"19","author":"Smee","year":"2008","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.antiviral.2006.09.008","article-title":"Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs","volume":"73","author":"Scagliarini","year":"2007","journal-title":"Antivir. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature04295","article-title":"Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection","volume":"439","author":"Stittelaar","year":"2006","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/JVI.00984-08","article-title":"Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox","volume":"83","author":"Wei","year":"2009","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.48.5.1869-1871.2004","article-title":"Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro","volume":"48","author":"Keith","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/AAC.49.2.656-662.2005","article-title":"Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro","volume":"49","author":"Wan","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/1535-7163.MCT-05-0200","article-title":"Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro","volume":"5","author":"Hostetler","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/AAC.50.4.1564-1566.2006","article-title":"Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro","volume":"50","author":"Randhawa","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1124\/mol.63.3.678","article-title":"Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism","volume":"63","author":"Aldern","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1086\/421912","article-title":"Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection","volume":"190","author":"Bidanset","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1128\/AAC.48.9.3516-3522.2004","article-title":"Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.48.2.404-412.2004","article-title":"Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir","volume":"48","author":"Quenelle","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tibtech.2004.06.008","article-title":"Design and development of oral drugs for the prophylaxis and treatment of smallpox infection","volume":"22","author":"Painter","year":"2004","journal-title":"Trends Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/AAC.39.6.1247","article-title":"Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients","volume":"39","author":"Cundy","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00003495-199958020-00015","article-title":"Cidofovir: A review of its use in cytomegalovirus retinitis in patients with AIDS","volume":"58","author":"Plosker","year":"1999","journal-title":"Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_60","first-page":"21","article-title":"Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis","volume":"65","author":"Brody","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1096-9071(199803)54:3<219::AID-JMV13>3.0.CO;2-C","article-title":"Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]","volume":"54","author":"Snoeck","year":"1998","journal-title":"J. Med. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1097\/00005537-200312000-00024","article-title":"Intralesional cidofovir and surgical excision for laryngeal papillomatosis","volume":"113","author":"Naiman","year":"2003","journal-title":"Laryngoscope"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/00005537-200407000-00004","article-title":"Cidofovir plasma assays after local injection in respiratory papillomatosis","volume":"114","author":"Naiman","year":"2004","journal-title":"Laryngoscope"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0166-3542(97)00022-3","article-title":"Bioavailability and metabolism of cidofovir following topical administration to rabbits","volume":"35","author":"Cundy","year":"1997","journal-title":"Antivir. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0","article-title":"Clinical uses of cidofovir","volume":"7","author":"Safrin","year":"1997","journal-title":"Rev. Med. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0166-3542(90)90069-J","article-title":"Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs","volume":"13","author":"Li","year":"1990","journal-title":"Antivir. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/infdis\/171.4.788","article-title":"(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I\/II study of a novel antiviral nucleotide analogue","volume":"171","author":"Lalezari","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1128\/AAC.39.4.882","article-title":"Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria","volume":"39","author":"Polis","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/infdis\/170.3.570","article-title":"Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS","volume":"170","author":"Lalezari","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/mol.56.3.570","article-title":"The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1","volume":"56","author":"Cihlar","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1081\/NCN-100002341","article-title":"Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs","volume":"20","author":"Cihlar","year":"2001","journal-title":"Nucleos. Nucleot. Nucleic Acids"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1681\/ASN.V113383","article-title":"Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1","volume":"11","author":"Ho","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s11095-006-9196-x","article-title":"Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2)","volume":"24","author":"Uwai","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199652020-00006","article-title":"Cidofovir","volume":"52","author":"Lea","year":"1996","journal-title":"Drugs"},{"key":"ref_75","first-page":"3","article-title":"A review of topical and intralesional cidofovir","volume":"6","author":"Zabawski","year":"2000","journal-title":"Dermatol. Online. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0190-9622(98)70046-5","article-title":"Topical and intralesional cidofovir: A review of pharmacology and therapeutic effects","volume":"39","author":"Zabawski","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/322593","article-title":"Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection","volume":"33","author":"Snoeck","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1468-3083.2000.00184.x","article-title":"Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV\/AIDS. A pilot study","volume":"14","author":"Calista","year":"2000","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00007890-200202270-00033","article-title":"Topical use of cidofovir induced acute renal failure","volume":"73","author":"Bienvenu","year":"2002","journal-title":"Transplantation"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM198703123161106","article-title":"Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease","volume":"316","author":"Redfield","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(06)68143-9","article-title":"Smallpox","volume":"367","author":"Moore","year":"2006","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm0507-517","article-title":"Dramatic rescue relieves rare case of smallpox infection","volume":"13","author":"Marris","year":"2007","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/587668","article-title":"Severe eczema vaccinatum in a household contact of a smallpox vaccinee","volume":"46","author":"Vora","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3201\/eid1212.060454","article-title":"Qualitative assessment of risk for monkeypox associated with domestic trade in certain animal species, United States","volume":"12","author":"Bernard","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1473-3099(03)00856-9","article-title":"Human monkeypox: An emerging zoonosis","volume":"4","author":"Eckburg","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpedi.159.11.1022","article-title":"Transmission of monkeypox among persons exposed to infected prairie dogs in Indiana in 2003","volume":"159","author":"Kile","year":"2005","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3201\/eid1505.090159","article-title":"Cowpox virus transmission from pet rats to humans, Germany","volume":"15","author":"Campe","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1610-0387.2007.06546.x","article-title":"Cowpox infection transmitted from a domestic cat","volume":"6","author":"Bonnekoh","year":"2008","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S1473-3099(10)70054-2","article-title":"Human cowpox in a veterinary student","volume":"10","author":"Glatz","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3201\/eid1505.090235","article-title":"Cowpox virus transmission from pet rats to humans, France","volume":"15","author":"Ninove","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1086\/595004","article-title":"17-year-old girl with a black eschar. Cowpox virus infection","volume":"48","author":"Strenger","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QCO.0b013e3282f44c74","article-title":"Cowpox virus infection: An emerging health threat","volume":"21","author":"Vorou","year":"2008","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archderm.1997.03890440061010","article-title":"Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir","volume":"133","author":"Meadows","year":"1997","journal-title":"Arch. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(99)01782-1","article-title":"Topical cidofovir for severe molluscum contagiosum","volume":"353","author":"Davies","year":"1999","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1525-1470.1999.016005406.7.x","article-title":"Topical cidofovir for molluscum contagiosum in children","volume":"16","author":"Zabawski","year":"1999","journal-title":"Pediatr. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/archderm.136.8.983","article-title":"Topical cidofovir: A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1","volume":"136","author":"Toro","year":"2000","journal-title":"Arch. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1468-3083.2004.00706.x","article-title":"Topical cidofovir and cryotherapy\u2014Combination treatment for recalcitrant molluscum contagiosum in a patient with HIV infection","volume":"18","author":"Baxter","year":"2004","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jmv.1084","article-title":"A case of human orf in an immunocompromised patient treated successfully with cidofovir cream","volume":"64","author":"Geerinck","year":"2001","journal-title":"J. Med. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1086\/517509","article-title":"Progressive ORF virus infection in a patient with lymphoma: successful treatment using imiquimod","volume":"44","author":"Lederman","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/315190","article-title":"Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge","volume":"181","author":"Bray","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.46.5.1329-1335.2002","article-title":"Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses","volume":"46","author":"Smee","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0166-3542(00)00105-4","article-title":"Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir","volume":"47","author":"Smee","year":"2000","journal-title":"Antivir. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000070618","article-title":"Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice","volume":"49","author":"Smee","year":"2003","journal-title":"Chemotherapy"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0166-3542(01)00220-0","article-title":"Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir","volume":"54","author":"Bray","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.47.9.2933-2937.2003","article-title":"Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge","volume":"47","author":"Roy","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0166-3542(01)00217-0","article-title":"Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug","volume":"54","author":"Smee","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1128\/AAC.47.10.3275-3280.2003","article-title":"Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice","volume":"47","author":"Quenelle","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2006.05.005","article-title":"Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection","volume":"72","author":"Knorr","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2007.11.013","article-title":"Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment","volume":"31","author":"Smee","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.virusres.2007.04.014","article-title":"In vivo imaging of cidofovir treatment of cowpox virus infection","volume":"128","author":"Goff","year":"2007","journal-title":"Virus Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF01967257","article-title":"Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice","volume":"12","author":"Neyts","year":"1993","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.antiviral.2004.02.003","article-title":"Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir","volume":"63","author":"Quenelle","year":"2004","journal-title":"Antivir. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.48.6.2267-2273.2004","article-title":"Efficacy of cidofovir in a murine model of disseminated progressive vaccinia","volume":"48","author":"Neyts","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1086\/422696","article-title":"Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice","volume":"190","author":"Smee","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2004.12.003","article-title":"The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4","volume":"66","author":"Robbins","year":"2005","journal-title":"Antivir. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"Parker","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_117","first-page":"A73","article-title":"Cidofovir (HPMPC) treatment of monkeypox","volume":"37","author":"Huggins","year":"1998","journal-title":"Antivir. Res."},{"key":"ref_118","first-page":"A57","article-title":"Successful cidofovir treatment of smallpox-like disease in variola and monkeypox primate models","volume":"62","author":"Huggins","year":"2004","journal-title":"Antivir. Res."},{"key":"ref_119","first-page":"A78","article-title":"Cidofovir treatment with vza-ariola (smallpox) in the hemorrhagic smallpox primate model and the IV monkeypox primate model","volume":"57","author":"Huggins","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_120","first-page":"A36","article-title":"Sequential determination of virus in blood and tissues of the variola cynomolgus monkey model of classical smallpox reveals that IV cidofovir can effectively treat monkeys with extensive viral burden","volume":"70","author":"Huggins","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1208\/s12248-009-9101-8","article-title":"Therapeutic paint of cidofovir\/sucralfate gel combination topically administered by spraying for treatment of orf virus infections","volume":"11","author":"Sonvico","year":"2009","journal-title":"AAPS. J."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/12\/2803\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:04:10Z","timestamp":1760220250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/12\/2803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,22]]},"references-count":121,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12]]}},"alternative-id":["v2122803"],"URL":"https:\/\/doi.org\/10.3390\/v2122803","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,22]]}}}